Provider Perspectives on Beta-lactam Therapeutic Drug Monitoring Programs in the Critically Ill

Mayo Clinic138 enrolled

Overview

The purpose of the study is to characterize various healthcare practitioners' perspectives on implementation of beta-lactam therapeutic drug monitoring in critical care practice.

Study Type

OBSERVATIONAL

Enrollment

138

Conditions

Sepsis Critical Illness

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Providers involved with beta-lactam TDM for critically ill patients Exclusion Criteria: * None

Locations (3)

UF Health Shands

Gainesville, Florida, United States

Mayo Clinic

Rochester, Minnesota, United States

Royal Brisbane and Women's Hospital

Herston, Queensland, Australia

Outcomes

Primary Outcomes

Frequency of drug level testing recommended

Indication of how many critically ill patients treated with beta-lactams should receive TDM.

Time frame: Baseline

Nature of drug level testing recommended

Indication of which types of critically ill patients treated with beta-lactams should receive TDM

Time frame: Baseline

Secondary Outcomes

Determinants of beta-lactam TDM implementation

List of factors associated with successful beta-lactam TDM implementation

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.